Lexpos News

MHRA Class 4 Medicines Defect Information: Parasolve (Paracetamol) 500mg effervescent tablets (Kent Pharma UK) Drug alert number: EL (24)A/51 Date issued: 28 October 2024 The Medicines and Health products Regulatory Agency (MHRA) has issued a class 4 medicines defect information notice for: Parasolve (Paracetamol) 500mg effervescent tablets (Kent Pharma UK) Company name: Kent Pharma UK Product [...]

The post MHRA Class 4 Medicines Defect Information: Parasolve (Paracetamol) 500mg effervescent tablets (Kent Pharma UK) appeared first on Community Pharmacy England.

As we celebrate Black History Month, we recognise the important contributions of Black colleagues across our sector. This month honours Black history, achievements and experiences, but it has also provided us a time to reflect and reaffirm our dedication to equality, diversity, and inclusion (EDI). Our Chief Executive Janet Morrison said: “At Community Pharmacy England, [...]

The post Honouring Black History Month and EDI appeared first on Community Pharmacy England.

A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (Vol 18 Issue 3 October 2024) has been published and includes articles on: GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuse. Insulin pumps and continuous glucose monitoring (CGM) equipment: guidance for users on [...]

The post MHRA: Drug Safety Update: October 2024 appeared first on Community Pharmacy England.

Minister Stephen Kinnock recently responded to a Parliamentary Question regarding pharmacy reimbursement. In his response, he stated that pharmacies were allowed to retain £850m medicine margin in the year 2023/24. The pharmacy funding settlement for 2022/23 and 2023/24 included an uplift to the Drug Tariff, as £100m in excess margin earned by the sector in [...]

The post Clarification regarding retained margin in 2023/24 appeared first on Community Pharmacy England.